Painkillers Prevent Cancer but Up Heart Risk
Anti-Inflammatory Drugs May Help Prevent Oral Cancer but Also Increase Heart Disease Risk
April 18, 2005 (Anaheim, Calif.) -- A new study adds to growing concerns
about the heart safety of painkillers taken by millions of Americans. It shows
that smokers who regularly take certain nonsteroidal anti-inflammatory drugs
(NSAIDs) double their risk of dying of heart disease.
The study, presented at the annual meeting of the American Association for
Cancer Research, was designed to test whether the anti-inflammatory drugs could
prevent oral cancer among heavy smokers.
It showed NSAIDs do indeed have that protective effect, reducing the risk of
oral cancers in smokers by about half. The analysis included aspirin, ibuprofen
(sold as Motrin, Advil, and others), naproxen (Aleve and others), indomethacin,
piroxicam, and ketoprofen. Acetaminophen (Tylenol) was also included but is not
Nevertheless, for most people seeking to reduce their risk of oral cancer,
the risks of taking NSAIDs appear to outweigh the benefits, says chief
investigator John Sudbo, MD, PhD, DDS, a cancer researcher at the Norwegian
Radium Hospital in Oslo.
Raymond DuBois MD, PhD, director of the Vanderbilt-Ingram Cancer Center and
moderator of a news conference about the findings, agrees.
"You don't want to do something that will make people worse," he
A better strategy against oral cancer would be to quit smoking, Sudbo tells
WebMD. "Smoking cessation is as effective at preventing oral cancer as
using NSAIDs. Both cut the risk by about 50%," he says.
Some Painkillers Pulled From Market
DuBois says the National Cancer Institute will host a meeting in May to
address emerging information about NSAID toxicity.
At first, heart risks seemed to be confined to a small group of NSAIDs
called Cox-2 inhibitors -- Bextra, Vioxx, and Celebrex. was pulled from the market last fall
when a study testing whether it could prevent recurrent colon polyps showed a
higher heart disease risk. Recently, manufacturer Pfizer stopped selling for heart safety reasons, but Pfizer's
Celebrex is still on the market.
The study's findings suggest that other types of NSAIDs also pose a risk to
Painkillers Lower Risk of Oral Cancer
The new study followed more than 3,000 smokers enrolled in the Norwegian
Cancer Registry, a database of more than 123,000 people.
Over a 20-year period, 454 of them developed oral cancer; they were compared
with 454 smokers who did not develop cancer. Of these 908 people, 277 were
long-term NSAID users, meaning they used the medications for at least six
The study showed that years of NSAID use were associated with lowered oral
cancer risk. Those who took NSAIDs for five years or less had about half the
risk for oral cancer compared with nonusers. Those who used them for 15 to 26
years were 70% less likely to develop oral cancer.